UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares saw an uptick in trading volume on Thursday . 2,448 shares were traded during trading, an increase of 213% from the previous session’s volume of 781 shares.The stock last traded at $286.7250 and had previously closed at $289.84.

Analyst Upgrades and Downgrades

Several research firms have issued reports on UCBJF. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday, February 16th. Wolfe Research began coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy”.

UCB Stock Down 1.1%

The firm has a 50-day moving average price of $295.05 and a 200 day moving average price of $296.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.